denosumab (Xgeva®)

Denosumab (Xgeva®) is recommended for use within NHS Wales for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.